The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Business
  • Construction
  • Entertainment
  • Legal
  • Sports

Actuated Medical Developing Technology to Improve Targeting for Next-Generation Alcohol Use Disorder Treatments
The PennZone/10278266

Trending...
  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
  • School Dental Screening Programs Conducted in Dubai
  • New Luxury Single Family Homes From $976,990 in Manalapan
Actuated Medical Inc.
BELLEFONTE, Pa. - PennZone -- Treating alcohol misuse remains a major challenge worldwide.  Given the diverse biological processes that contribute to alcohol use disorder, new medications are needed to provide a broader spectrum of treatment options. Some people may respond to a medication that helps with craving, others may respond to a medication that relieves impulsivity, others may respond to a medication that reverses the negative emotional state of withdrawal or protracted withdrawal. Just like any other medical condition, people with alcohol use disorder deserve to have a range of treatment options available to them. Scientists are working to develop a larger menu of pharmaceutical treatments that could be tailored to individual needs.

Actuated Medical's innovative NeuralGlider Injector will enable the delivery of next-generation medications into small targets deep in the brain, to fundamentally change the trajectory of alcohol use disorder and improve outcomes.  The goal is to deliver a therapeutic that will damp down cravings enough for other therapies to have a chance to work.  The therapeutic gets delivered accurately to the target and stays there.

Actuated Medical, Inc. has been awarded a $3 million pre-clinical Phase II Small Business Innovative Research (SBIR) grant from the National Institutes of Health-National Institute on Alcohol Abuse and Alcoholism to develop the "Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS (designer receptors exclusively activated by designer drugs) Therapy in Alcohol Addiction Treatment" which will be commercially recognized as the NeuralGlider Injector.

More on The PennZone
  • UK Financial Ltd Publishes Maya Preferred Public Proof Package and CoinMarketCap Supply Verification Evidence
  • Justice Advisory Group Expands Federal Sentencing, Prison Preparation and Reentry Support Services
  • Advancing High-Potential Nevada Critical Minerals Portfolio as Major Drill Program Nears Assay Results: Glenstar Minerals: Stock Symbol: GSTRF
  • Allstream Energy Partners to Host 6th Executive Networking After 2026 Energy Projects Conference
  • CAPHRA: Australia and Thailand show nicotine prohibition fuels illicit markets

"Many of us know someone who is dealing with an alcohol addiction and have felt helpless as we watched them suffer. That is why we are so excited to develop and commercialize our NeuralGlider Injector technology as it may one day help to offer a more effective treatment option for those afflicted with alcohol use disorder." Maureen L. Mulvihill, Ph.D., Actuated Medical President, CEO, & Co-Founder.

About Actuated Medical, Inc.

Actuated Medical is a Pennsylvania medical device product innovator founded in 2006 on the entrepreneurial idea that electronically controlled motion can solve clinical needs and improve patient outcomes. They are developing products in the areas of neuroscience, critical care, gastroenterology, and pediatrics. Their Actuated Neuroscience Division focuses on developing tools to assist researchers in understanding neurological conditions. Recently, they were awarded a 5-year Contract under the National Institutes of Health (NIH) Blueprint MedTech (BPMT) initiative to assist brain researchers conduct their FDA compliant testing. Actuated has 42 issued patents and 7 FDA 510(k) clearances. They have been the recipient of a 2014 & 2020 SBA Tibbets Awards for SBIR commercialization excellence. Actuated's CEO was the 2020 Life Sciences Pennsylvania CEO of the Year due to the teams Covid PPE pivot.

More on The PennZone
  • Custom Disposables - Wholesale Packaging Solutions for restaurants, food chains, and food distributors
  • California Security Glass is an affordable bulletproof glass installation company in LA serving a variety of neighboring cities
  • Allstream Energy Partners Announce Media Partnership with the 2026 EPC Show - The Energy Projects Conference
  • STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry
  • West Virginia Leaders Announce Support for Election Integrity Network's Model Election Laws Handbook

More information about Actuated neural device innovations.

See www.actuatedneuroscience.com

NIH Disclaimer.

Research reported in this publication was supported by the National Institute On Alcohol Abuse And Alcoholism of the National Institutes of Health under Award Number R44AA030512. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

###

For more information about this topic, please contact Maureen L. Mulvihill, Ph.D. by phone at 814-355-0003 or email at info@actuatedmedical.com.

Additional information can be found by visiting:

https://actuatedmedical.com

https://actuatedneuroscience.com

Contact
Actuated Medical
***@actuatedmedical.com


Source: Actuated Medical, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • What Would you Do with Your Time if it Was Actually Money?
  • Mr. Hospital Bed Showcases the Best Hospital Bed and Air Mattress for Bed Sores for 2026
  • Traian TKD Tractari Auto Iasi: cum transporti legal la RAR o masina fara numere sau cu ITP expirat
  • Mike Williams Golf Center Now Open at Georgia's Lanier Islands Resort
  • Appliance EMT Launches June "Summer Rescue" Promotion
  • New Luxury Single Family Homes From $976,990 in Manalapan
  • Longevityresearch.ca Unveils a Unique Bayesian Causal Atlas; Saves up to 7.9 life years/patient
  • Grane Rx, a National Pharmacy Partner to PACE Programs, Names Scott Sosso President
  • K2 Integrity Acquires RiskFront AI to Deliver AI Automation for Financial Crime Compliance and Risk Operations
  • HousingWire acquires Keeping Current Matters, putting local market data into the tools agents use to win listings
  • KIDZONET & Ocean Telecom Launch UK First eSIM Child Protection — EasySim AI Safe SIM Cards
  • School Dental Screening Programs Conducted in Dubai
  • British Brand Daniel Mason™ Expands Premium Braided Leather Belt Collection Internationally
  • Looking for expert pool tiling in Gold Coast? Call Avid Tiling
  • Hosted Network Powers National Growth with netElastic vBNG, CGNAT and netVision
  • Individual Entrepreneur of Annville, PA, Acquires Mosquito Joe of Lancaster, PA
  • Super Lawyers Recognizes Inman & Tourgee Attorneys Mark Tourgee and Jacob Rinn
  • PropAccount.com Launches PropGenie, the First Branding Studio Built for Prop Firm Operators
  • Rushing Headlong: Health IT's Legacy and the Road to Responsible AI is named 2025 Foreword INDIES Book of the Year Awards Winner
  • The Problem With AI Isn't Compute. It's Memory

Popular on PennZone

  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan - 169
  • Love Must Be the Guide: Live Good Shares a Message of Humanity, Compassion and Hope
  • Calvetta Phair, CEO America's Workforce Solution, LLC Assessed "Awardable" for Department of War work in the CDAO's Tradewinds Solutions Marketplace
  • Thou Shalt not Commit Adultery Lifetime Movie Discussion
  • Lansdowne Photographer Steven Weisz Selected for Philadelphia City Hall Exhibition
  • AI Is Closing the Gap Between Offshore Virtual Assistants and Onshore Staff
  • Joseph Nybyk (AKA Joseph Neibich) Guests On Octopus TV
  • SteelTree Announces Launch of Its Operational Decision Intelligence Service
  • Autism Podcast Helps Parents Understand Why Behavior Is Communication, Not Defiance
  • Tennessee Laws Lead with Psychotropic Drug Testing in Mass Shooting Cases and Comprehensive Reporting: CCHR Urges Nationwide Adoption

Similar on PennZone

  • purelyIV Expands Mobile IV Therapy to Jackson, MI and Launches PlaqueX® IV Therapy
  • UK Financial Ltd Publishes Maya Preferred Public Proof Package and CoinMarketCap Supply Verification Evidence
  • CAPHRA: Australia and Thailand show nicotine prohibition fuels illicit markets
  • CCHR Condemns Behavioral Treatment After FDA's Missed Deadline to Ban Shock Device
  • Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
  • Dr. Stephen Shainbart Launches Expanded Mental Health Support for Anxiety and Depression in Toronto
  • Mr. Hospital Bed Showcases the Best Hospital Bed and Air Mattress for Bed Sores for 2026
  • Longevityresearch.ca Unveils a Unique Bayesian Causal Atlas; Saves up to 7.9 life years/patient
  • K2 Integrity Acquires RiskFront AI to Deliver AI Automation for Financial Crime Compliance and Risk Operations
  • Rushing Headlong: Health IT's Legacy and the Road to Responsible AI is named 2025 Foreword INDIES Book of the Year Awards Winner
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us